| scholarly article | Q13442814 |
| P2093 | author name string | Renshaw PF | |
| Satlin A | |||
| Bodick N | |||
| Offen WW | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | spectroscopy | Q483666 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 1459-1461 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist | |
| P478 | volume | 154 |
| Q37398605 | 1H MR spectroscopy in common dementias |
| Q37150637 | 1H magnetic resonance spectroscopy in dementia |
| Q30635401 | A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 mice |
| Q37459037 | APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain. |
| Q31159878 | Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements |
| Q30585268 | Brain biochemistry using magnetic resonance spectroscopy: relevance to psychiatric illness in the elderly |
| Q40285261 | Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy |
| Q34677583 | Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention |
| Q53656292 | Elevated Choline-Containing Compound Levels in Rapid Cycling Bipolar Disorder. |
| Q92671500 | Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease |
| Q44043942 | Hydrogen proton magnetic resonance spectroscopy in autism: preliminary evidence of elevated choline/creatine ratio |
| Q30815106 | Imaging of Alzheimer's disease |
| Q48396205 | La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease |
| Q37398634 | Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease |
| Q48665796 | Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment |
| Q36971142 | Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine |
| Q36598509 | MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases |
| Q30660816 | Magnetic resonance imaging and magnetic resonance spectroscopy in dementias |
| Q30630699 | Magnetic resonance spectroscopy in Alzheimer's disease |
| Q30660402 | Magnetic resonance spectroscopy in common dementias |
| Q35210272 | Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults |
| Q30673059 | Magnetic resonance spectroscopy: current and future applications in psychiatric research |
| Q31047131 | Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics |
| Q45732943 | Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET. |
| Q48103250 | Muscarinic receptor dependent long-term depression in rat visual cortex is PKC independent but requires ERK1/2 activation and protein synthesis |
| Q36064806 | Neurochemical changes in the pericalcarine cortex in congenital blindness attributable to bilateral anophthalmia |
| Q30408825 | Neurochemical changes within human early blind occipital cortex |
| Q30989943 | Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease |
| Q37661367 | Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). |
| Q30606675 | Proton MRS in mild cognitive impairment |
| Q44693595 | Proton magnetic resonance spectroscopic imaging of the brain in childhood autism |
| Q30593705 | Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review. |
| Q30983010 | Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease |
| Q37418999 | The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES). |
| Q41288398 | ¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease |
Search more.